Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212

The MEK1 and MEK2 inhibitor GSK1120212 is currently in phase II/III clinical development. To identify predictive biomarkers, sensitivity to GSK1120212 was profiled for 218 solid tumor cell lines and 81 hematologic malignancy cell lines. For solid tumors, RAF/RAS mutation was a strong predictor of sensitivity. Among RAF/RAS mutant lines, co-occurring PIK3CA/PTEN mutations conferred a cytostatic response instead of a cytotoxic response for colon cancer cells that have the biggest representation of the comutations. Among KRAS mutant cell lines, transcriptomics analysis showed that cell lines with an expression pattern suggestive of epithelial-to-mesenchymal transition were less sensitive to GSK1120212. In addition, a proportion of cell lines from certain tissue types not known to carry frequent RAF/RAS mutations also seemed to be sensitive to GSK1120212. Among these were breast cancer cell lines, with triple negative breast cancer cell lines being more sensitive than cell lines from other breast cancer subtypes. We identified a single gene DUSP6, whose expression was associated with sensitivity to GSK1120212 and lack of expression associated with resistance irrelevant of RAF/RAS status. Among hematologic cell lines, acute myeloid leukemia and chronic myeloid leukemia cell lines were particularly sensitive. Overall, this comprehensive predictive biomarker analysis identified additional efficacy biomarkers for GSK1120212 in RAF/RAS mutant solid tumors and expanded the indication for GSK1120212 to patients who could benefit from this therapy despite the RAF/RAS wild-type status of their tumors. Mol Cancer Ther; 11(3); 720–9. ©2011 AACR.

[1]  H. Uramoto,et al.  Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. , 2011, Lung cancer.

[2]  M. Sznol.  Molecular Markers of Response to Treatment for Melanoma , 2011, Cancer journal.

[3]  Shu Ichihara,et al.  Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists , 2011, Modern Pathology.

[4]  Francesca Zappacosta,et al.  GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition , 2011, Clinical Cancer Research.

[5]  Aik Choon Tan,et al.  Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer , 2010, Molecular Cancer Therapeutics.

[6]  W. Sellers,et al.  PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. , 2010, Cancer research.

[7]  Kwang-Hyun Cho,et al.  Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. , 2010, Cancer Research.

[8]  D. Elashoff,et al.  Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines , 2010, Molecular Cancer Therapeutics.

[9]  T. Yap,et al.  Targeting the HGF/c-Met Axis: State of Play , 2010, Molecular Cancer Therapeutics.

[10]  Joel Greshock,et al.  Molecular target class is predictive of in vitro response profile. , 2010, Cancer research.

[11]  B. Taylor,et al.  Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). , 2010, Cancer research.

[12]  K. Takeuchi,et al.  EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR‐targeting tyrosine kinase inhibitors , 2010, The FEBS journal.

[13]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.

[14]  A. Brufsky.  Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer: From Early Scientific Development to Foundation of Care , 2009, American journal of clinical oncology.

[15]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[16]  W. Sellers,et al.  PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. , 2009, Cancer research.

[17]  C. García-echeverría,et al.  PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. , 2009, Current opinion in cell biology.

[18]  C. Sander,et al.  V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.

[19]  T. Furukawa,et al.  Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells. , 2008, Biochemical and biophysical research communications.

[20]  David B Solit,et al.  Therapeutic strategies for inhibiting oncogenic BRAF signaling. , 2008, Current opinion in pharmacology.

[21]  O. De Wever,et al.  Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[22]  M. Moasser.  Targeting the function of the HER2 oncogene in human cancer therapeutics , 2007, Oncogene.

[23]  A. Martin,et al.  Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines , 2007, Cell proliferation.

[24]  藤田 至彦.  What's going on 癌細胞が増殖や生存を維持するためにSrc、BCR-ABL、EGF受容体に依存する現象には、共通するシグナル伝達機構が介在することを見出した論文[Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J'A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes'] , 2007 .

[25]  K. Siziopikou,et al.  The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. , 2007, Breast.

[26]  D. Haber,et al.  A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. , 2006, Cancer cell.

[27]  F. Bertucci,et al.  Gene expression profiling of breast cell lines identifies potential new basal markers , 2006, Oncogene.

[28]  Shinichirou Takahashi.  Inhibition of the MEK/MAPK signal transduction pathway strongly impairs the growth of Flt3‐ITD cells , 2006, American journal of hematology.

[29]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[30]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[31]  S. Schwartz,et al.  The prevalence of PIK3CA mutations in gastric and colon cancer. , 2005, European journal of cancer.

[32]  M. Ellis,et al.  Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[36]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[37]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.